Literature DB >> 3116658

The renal handling of sodium and water is not affected by the standard-dose cisplatin treatment for testicular cancer.

G Daugaard1, S Strandgaard, N H Holstein-Rathlou, P L Frederiksen, U G Svendsen, O Munck, P P Leyssac.   

Abstract

Renal clearances of 51Cr-EDTA, lithium, sodium and potassium were measured before and after each of four consecutive treatment series with cisplatin in 15 men with testicular cancer. Since lithium is reabsorbed like sodium and water in the proximal tubules, but not reabsorbed to any measurable degree in the remainder of the nephron, lithium clearance equals the amount of fluid delivered from the end of the proximal straight segment to the thin descending limb of the loop of Henle. From the clearances of lithium and sodium, distal tubular reabsorption can be calculated. Lithium clearance and all other parameters of glomerular filtration and renal sodium handling remained normal throughout the study (with the exception of a fall in fractional sodium excretion after the first treatment series). Plasma magnesium declined during all four treatment periods, signifying renal magnesium wasting.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3116658

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  3 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Antitumour response and nephrotoxicity following intraperitoneal administration of a slow release formulation of cisplatin to rats bearing cancers restricted to the peritoneal cavity.

Authors:  G Los; W Kop; M J Deurloo
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

3.  Effect of oral administration of magnesium on Cisplatin-induced nephrotoxicity in normal and streptozocin-induced diabetic rats.

Authors:  Nepton Soltani; Mehdi Nematbakhsh; Fatemeh Eshraghi-Jazi; Ardeshir Talebi; Farzaneh Ashrafi
Journal:  Nephrourol Mon       Date:  2013-08-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.